MYIA
KRYS icon

Mount Yale Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Mount Yale Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
1,204
+74
+7% +$22.1K 0.01% 824
2026
Q1 		$292K Buy
+1,130
New +$301K 0.01% 907
2025
Q3 		– Sell
-1,251
Closed -$172K – 1173
2025
Q2 		$172K Buy
1,251
+12
+1% +$1.76K 0.01% 564
2025
Q1 		$223K Buy
+1,239
New +$208K 0.02% 496
2024
Q4 		– Sell
-1,027
Closed -$187K – 593
2024
Q3 		$187K Buy
+1,027
New +$198K 0.02% 530

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mount Yale Investment Advisors's KRYS Position: Q2 2026 in Review

Mount Yale Investment Advisors increased its Krystal Biotech (KRYS) stake by 6.5% in Q2 2026, buying an estimated $22.1K and bringing the position to 1,204 shares worth $447K. The position accounts for 0.01% of the portfolio, ranked #824.

Mount Yale Investment Advisors first reported a position in KRYS in Q3 2024 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Mount Yale Investment Advisors held 1,204 shares of Krystal Biotech worth $447K as of Q2 2026.
  • Mount Yale Investment Advisors bought 74 Krystal Biotech shares in Q2 2026, an estimated $22.1K.
  • Krystal Biotech made up 0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #824 holding.
  • Mount Yale Investment Advisors first reported a position in Krystal Biotech in Q3 2024 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.